UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Cancer treatment reviews, 2020-11, Vol.90, p.102105-102105, Article 102105

2020

Volltextzugriff (PDF)

Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

Journal of thoracic oncology, 2019-07, Vol.14 (7), p.1244-1254

2019

Volltextzugriff (PDF)

Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

Nature reviews. Clinical oncology, 2023-10, Vol.20 (10), p.664-677

2023

Volltextzugriff (PDF)

Automated detection and segmentation of non-small cell lung cancer computed tomography images

Nature communications, 2022-06, Vol.13 (1), p.3423-3423, Article 3423

2022

Volltextzugriff (PDF)

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-10, Vol.36 (28), p.2872-2878

2018

Volltextzugriff (PDF)

Management of stage I and II nonsmall cell lung cancer

The European respiratory journal, 2017-01, Vol.49 (1), p.1600764-1600764

2017

Volltextzugriff (PDF)

Speeding up Antibody-Drug Conjugate Development in Pretreated EGFR -Mutant Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2023-12, Vol.41 (35), p.5351-5355

2023

Volltextzugriff (PDF)

The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?

Journal of clinical oncology, 2023-02, Vol.41 (6), p.1176-1179

2023

Volltextzugriff (PDF)

Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?

European journal of cancer (1990), 2022-05, Vol.167, p.149-151

2022

Volltextzugriff (PDF)

Paving the Way for Long-Term Survival in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2021-07, Vol.39 (21), p.2321-2323

2021

Volltextzugriff (PDF)

Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors

European journal of cancer (1990), 2019-07, Vol.116, p.182-189

2019

Volltextzugriff (PDF)

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease

European journal of cancer (1990), 2019-11, Vol.122, p.109-114

2019

Volltextzugriff (PDF)

MET alterations in NSCLC—Current Perspectives and Future Challenges

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.419-435

2023

Volltextzugriff (PDF)

Targeted adjuvant therapy in non-small cell lung cancer: trick or treat?

The European respiratory journal, 2021-10, Vol.58 (4), p.2101637

2021

Volltextzugriff (PDF)

Screening for brain metastases in patients with stage III non–small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study

European journal of cancer (1990), 2019-07, Vol.115, p.88-96

2019

Volltextzugriff (PDF)

Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm

The European respiratory journal, 2020-02, Vol.55 (2), p.1901907

2020

Volltextzugriff (PDF)

Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy

Translational lung cancer research, 2018-12, Vol.7 (5), p.647-660

2018

Volltextzugriff (PDF)

Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.368-370

2021

Volltextzugriff (PDF)

A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2024-04, Vol.118 (5), p.1455-1460

2024

Volltextzugriff (PDF)

Biomarkers of Radiotherapy-Induced Immunogenic Cell Death

Cells (Basel, Switzerland), 2021-04, Vol.10 (4), p.930

2021

Volltextzugriff (PDF)

Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations

European journal of cancer (1990), 2023-05, Vol.184, p.172-178

2023

Volltextzugriff (PDF)

Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis

European journal of cancer (1990), 2023-02, Vol.180, p.117-124

2023

Volltextzugriff (PDF)

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring

European journal of cancer (1990), 2018-03, Vol.91, p.92-98

2018

Volltextzugriff (PDF)

Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?

Therapeutic Advances in Medical Oncology, 2022, Vol.14, p.17588359221113268

2022

Volltextzugriff (PDF)

Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials

Cancer treatment reviews, 2024-09, Vol.129, p.102797, Article 102797

2024

Volltextzugriff (PDF)

1 – 25 von 209

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(191)

Publikationsform

Artikel
(207)
Bücher
(1)
Berichte
(1)

Sprache

Englisch
(207)
Niederländisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(160)
Life Sciences & Biomedicine
(159)
Oncology
(134)
Humans
(77)
Respiratory System
(55)
Non-Small Cell Lung Cancer
(48)
Lung Cancer
(47)
Lung Neoplasms - Drug Therapy
(31)
Non-Small Cell Lung Carcinoma
(30)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(28)
Immunotherapy
(28)
Lung Neoplasms - Pathology
(26)
Nsclc
(26)
Small Cell Lung Carcinoma
(25)
Clinical Trials
(24)
Chemotherapy
(23)
Neoplasm Staging
(23)
Female
(22)
Metastasis
(22)
Patients
(22)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

Automated detection and segmentation of non-small cell lung cancer computed tomography images

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Management of stage I and II nonsmall cell lung cancer

Speeding up Antibody-Drug Conjugate Development in Pretreated EGFR -Mutant Non-Small-Cell Lung Cancer

The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?

Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?

Paving the Way for Long-Term Survival in Non–Small-Cell Lung Cancer

Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease

MET alterations in NSCLC—Current Perspectives and Future Challenges

Targeted adjuvant therapy in non-small cell lung cancer: trick or treat?

Screening for brain metastases in patients with stage III non–small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study

Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm

Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy

Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC

A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer

Biomarkers of Radiotherapy-Induced Immunogenic Cell Death

Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations

Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring

Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?

Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials

Suchergebnisse filtern